BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15870485)

  • 21. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.
    Olavarria E; Parker S; Craddock C; Philpott N; Tiniakou M; Chase A; Kanfer E; Apperley JF; Goldman JM
    Haematologica; 2000 Jun; 85(6):647-52. PubMed ID: 10870123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
    Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
    Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
    Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
    de Botton S; Fawaz A; Chevret S; Dombret H; Thomas X; Sanz M; Guerci A; San Miguel J; de la Serna J; Stoppa AM; Reman O; Stamatoulas A; Fey M; Cahn JY; Sotto JJ; Bourhis JH; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2005 Jan; 23(1):120-6. PubMed ID: 15534358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
    Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C
    Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kröger N; Krüger W; Wacker-Backhaus G; Hegewisch-Becker S; Stockschläder M; Fuchs N; Rüssmann B; Renges H; Dürken M; Bielack S; de Wit M; Schuch G; Bartels H; Braumann D; Kuse R; Kabisch H; Erttmann R; Zander AR
    Bone Marrow Transplant; 1998 Dec; 22(11):1029-33. PubMed ID: 9877263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
    Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion.
    Carella AM; Podestà M; Frassoni F; Pungolino E; Pollicardo N; Raffo MR; Ferrero R; Benvenuto F; Figari O; Giordano D
    Stem Cells; 1993 Oct; 11 Suppl 3():67-72. PubMed ID: 7905325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
    Kalayoglu-Besisik S; Ozturk GB; Caliskan Y; Nalcaci M; Gurses N; Cin N; Ozbek U; Sargin D
    Transfus Apher Sci; 2007 Feb; 36(1):91-4. PubMed ID: 17222585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT.
    Reiffers J; Goldman J; Meloni G; Cahn JY; Gratwohl A
    Bone Marrow Transplant; 1994 Sep; 14(3):407-10. PubMed ID: 7994263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.
    Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL
    Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors influencing feasibility of cytogenetic and molecular analysis in leukapheresis products in chronic myelogenous leukemia patients.
    Carrasco M; Sureda A; Martínez C; Carmona M; Altés A; Martín-Henao GA; Aventín A; Sierra J
    Ann Hematol; 2002 Dec; 81(12):710-6. PubMed ID: 12483367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
    Olsson-Strömberg U; Höglund M; Björkholm M; Braide I; Carlson K; Gahrton G; Grimfors G; Hast R; Lerner R; Linder O; Ljungman P; Löfvenberg E; Malm C; Nilsson PG; Paul C; Rödjer S; Stenke L; Tidefeldt U; Turesson I; Uden AM; Wahlin A; Vilen L; Winqvist I; Zettervall O; Oberg G; Simonsson B
    Leuk Lymphoma; 2006 Sep; 47(9):1768-73. PubMed ID: 17064986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia.
    Mahon FX; Fabères C; Montastruc M; Si-Mour S; Boiron JM; Marit G; Bilhou-Nabera C; Cony-Makhoul P; Pigneux A; Bernard P; Broustet A; Reiffers J
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S33-7. PubMed ID: 8769698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].
    Creutzig U; Ritter J; Zimmermann M; Klingebiel T
    Klin Padiatr; 1996; 208(4):236-41. PubMed ID: 8926689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Cottafavi L; Dotti GP; Rizzoli V
    Bone Marrow Transplant; 1994 Sep; 14(3):425-32. PubMed ID: 7994267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.